Global Minimal Residual Disease Market Report 2025

Minimal Residual Disease Global Market Report 2025 - By Detection Target (Lymphoma, Leukemia, Solid Tumors, Other Detection Targets), By Test Technique (Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques), By End-User (Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions) - Market Size, Trends, And Global Forecast 2025-2034

Minimal Residual Disease Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : March 2025 | Delivery Time: 2-3 business days | Format : pdf

Need assistance or more information before the purchase?

Enquire Before Buying
Minimal Residual Disease Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN

What Is Covered Under Minimal Residual Disease Market

Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse.

The main types of detection targets for minimal residual disease are lymphoma, leukemia, solid tumors, and others. Lymphoma is a cancer originating in the lymphatic system, primarily targeting white blood cells known as lymphocytes. The various test techniques include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and others and are used by several end-users, including banking, financial services, and insurance (BFSI), retail and e-commerce, hospitals, diagnostic laboratories, and research institutions.

How Is The Minimal Residual Disease Market Segmented?

The minimal residual disease market covered in this report is segmented –

1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets

2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques

3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions

Subsegments:

1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma

2) By Leukemia: Acute Lymphoblastic Leukemia, acute myeloid leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia

3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer

4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas

Minimal Residual Disease Market Size and growth rate 2025 to 2029: Graph

What Is The Minimal Residual Disease Market Size 2025 And Growth Rate?

The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing number of cancer patients, growing research and development spending, rising healthcare affordability, rising prevalence of blood cancer, and increasing awareness among people.

What Is The Minimal Residual Disease Market Growth Forecast?

The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to rise in the number of patients with cancer, rise in the government awareness programs, rise in the healthcare affordability, increasing disposable income in emerging economies, and government body initiatives to create awareness about cancer. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, adoption of personalized MRD monitoring, development in liquid biopsy technologies, minimal residual disease-directed therapies.

What Is Driving The Minimal Residual Disease Market: Rising Cancer Prevalence Driving Growth In The Market

The increasing prevalence of cancer is expected to propel the growth of the minimal residual disease market going forward. Cancer is a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The increasing prevalence of cancer is due to factors such as an aging population, increased exposure to environmental carcinogens, unhealthy lifestyles, and genetic predispositions. The rising cancer prevalence increases the demand for precise MRD testing to detect residual cancer cells, enabling early intervention and personalized treatment. This improves relapse prediction and enhances patient outcomes. For instance, in May 2024, according to the National Cancer Institute (NCI), a US-based government agency, in 2022 nearly 20 million new cancer cases and 9.7 million cancer-related deaths were reported globally, with projections for 2040 estimating 29.9 million new cases and 15.3 million cancer-related deaths. Therefore, the increasing prevalence of cancer is driving the growth of the minimal residual disease market.

Who Are The Major Players In The Global Minimal Residual Disease Market?

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.

What Are The Key Trends Of The Global Minimal Residual Disease Market: Advanced In Vitro Diagnostic (IVD) Test Services For Minimal Residual Disease (MRD) Detection In Diffuse Large B-Cell Lymphoma

Major companies operating in the minimal residual disease (MRD) market are focusing on developing advanced in vitro diagnostic (IVD) test services to provide personalized therapy options for better patient outcomes. An in vitro diagnostic (IVD) test service is a lab-based diagnostic method to detect residual cancer cells after treatment, helping predict relapse and optimize therapy. For instance, in December 2022, Adaptive Biotechnologies Corporation, a US-based biotechnology company, launched clonoSEQ Assay to detect minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). This test analyzes circulating tumor DNA (ctDNA) in blood samples to provide a highly sensitive, non-invasive way to monitor cancer progression and detect early signs of relapse. This assay offers clinicians a more precise understanding of a patient’s disease burden, helping them tailor treatment plans accordingly. It is the first minimal residual disease (MRD) test for diffuse large B-cell lymphoma (DLBCL) to receive Medicare coverage, making it widely accessible across all treatment regimens and time points.

What Are Latest Mergers And Acquisitions In The Minimal Residual Disease Market: Veracyte Acquired C2i Genomics To Enhance Cancer Diagnostics With MRD Expertise

In February 2024, Veracyte, Inc., a US-based cancer diagnostics company, acquired C2i Genomics, Inc. for $70 million. The acquisition integrates C2i Genomics' whole-genome minimal residual disease (MRD) expertise into Veracyte's diagnostic platform, strengthening its capacity to support patients across all stages of cancer care. C2i Genomics, Inc. is a US-based cancer intelligence company that provides a minimal residual disease (MRD) test.

What Is The Regional Outlook For The Global Minimal Residual Disease Market?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the minimal residual disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Minimal Residual Disease  Market?

The minimal residual disease market consists of revenues earned by entities by providing services such as cancer monitoring, relapse prediction, personalized treatment plans, and clinical trials. The market value includes the value of related goods sold by the service provider or included within the service offering. The minimal residual disease market also includes sales of clonality testing kits, MRD detection reagents, and MRD detection panels. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Minimal Residual Disease  Industry?

The minimal residual disease market research report is one of a series of new reports from The Business Research Company that provides minimal residual disease market statistics, including the minimal residual disease industry global market size, regional shares, competitors with the minimal residual disease market share, detailed minimal residual disease market segments, market trends, and opportunities, and any further data you may need to thrive in the minimal residual disease industry. This minimal residual disease market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Minimal Residual Disease Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $2.01 billion
Revenue Forecast In 2034 $3.22 billion
Growth Rate CAGR of 12.5% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc.
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Minimal Residual Disease Market Characteristics

    3. Minimal Residual Disease Market Trends And Strategies

    4. Minimal Residual Disease Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

    5. Global Minimal Residual Disease Growth Analysis And Strategic Analysis Framework

    5.1. Global Minimal Residual Disease PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Minimal Residual Disease Market Growth Rate Analysis

    5.4. Global Minimal Residual Disease Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Minimal Residual Disease Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Minimal Residual Disease Total Addressable Market (TAM)

    6. Minimal Residual Disease Market Segmentation

    6.1. Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Lymphoma

    Leukemia

    Solid Tumors

    Other Detection Targets

    6.2. Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Flow Cytometry

    Polymerase Chain Reaction (PCR)

    Next Generation Sequencing (NGS)

    Other Test Techniques

    6.3. Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Banking, Financial Services, And Insurance (BFSI)

    Retail And E-Commerce

    Hospitals

    Diagnostic Laboratories

    Research Institutions

    6.4. Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hodgkin Lymphoma

    Non-Hodgkin Lymphoma

    6.5. Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Acute Lymphoblastic Leukemia

    Acute Myeloid Leukemia

    Chronic Lymphocytic Leukemia

    Chronic Myeloid Leukemia

    6.6. Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Breast Cancer

    Lung Cancer

    Colorectal Cancer

    Prostate Cancer

    6.7. Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Multiple Myeloma

    Neuroblastoma

    Sarcom

    7. Minimal Residual Disease Market Regional And Country Analysis

    7.1. Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Minimal Residual Disease Market

    8.1. Asia-Pacific Minimal Residual Disease Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Minimal Residual Disease Market

    9.1. China Minimal Residual Disease Market Overview

    9.2. China Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Minimal Residual Disease Market

    10.1. India Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Minimal Residual Disease Market

    11.1. Japan Minimal Residual Disease Market Overview

    11.2. Japan Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Minimal Residual Disease Market

    12.1. Australia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Minimal Residual Disease Market

    13.1. Indonesia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Minimal Residual Disease Market

    14.1. South Korea Minimal Residual Disease Market Overview

    14.2. South Korea Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Minimal Residual Disease Market

    15.1. Western Europe Minimal Residual Disease Market Overview

    15.2. Western Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Minimal Residual Disease Market

    16.1. UK Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Minimal Residual Disease Market

    17.1. Germany Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Minimal Residual Disease Market

    18.1. France Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Minimal Residual Disease Market

    19.1. Italy Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Minimal Residual Disease Market

    20.1. Spain Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Minimal Residual Disease Market

    21.1. Eastern Europe Minimal Residual Disease Market Overview

    21.2. Eastern Europe Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Minimal Residual Disease Market

    22.1. Russia Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Minimal Residual Disease Market

    23.1. North America Minimal Residual Disease Market Overview

    23.2. North America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Minimal Residual Disease Market

    24.1. USA Minimal Residual Disease Market Overview

    24.2. USA Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Minimal Residual Disease Market

    25.1. Canada Minimal Residual Disease Market Overview

    25.2. Canada Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Minimal Residual Disease Market

    26.1. South America Minimal Residual Disease Market Overview

    26.2. South America Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Minimal Residual Disease Market

    27.1. Brazil Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Minimal Residual Disease Market

    28.1. Middle East Minimal Residual Disease Market Overview

    28.2. Middle East Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Minimal Residual Disease Market

    29.1. Africa Minimal Residual Disease Market Overview

    29.2. Africa Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Minimal Residual Disease Market Competitive Landscape And Company Profiles

    30.1. Minimal Residual Disease Market Competitive Landscape

    30.2. Minimal Residual Disease Market Company Profiles

    30.2.1. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Laboratory Corporation of America Holdings (LabCorp) Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. Quest Diagnostics Incorporated Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Agilent Technologies Inc. Overview, Products and Services, Strategy and Financial Analysis

    31. Minimal Residual Disease Market Other Major And Innovative Companies

    31.1. Sysmex Corporation

    31.2. Bio-Rad Laboratories Inc.

    31.3. Qiagen N.V.

    31.4. Exact Sciences Corporation

    31.5. Kite Pharma Inc.

    31.6. Natera Inc.

    31.7. Foundation Medicine Inc.

    31.8. NeoGenomics Inc.

    31.9. Guardant Health Inc.

    31.10. Grail LLC

    31.11. Tempus AI Inc.

    31.12. Veracyte Inc.

    31.13. Adaptive Biotechnologies Corporation

    31.14. Invivoscribe Inc.

    31.15. Mission Bio Inc.

    32. Global Minimal Residual Disease Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Minimal Residual Disease Market

    34. Recent Developments In The Minimal Residual Disease Market

    35. Minimal Residual Disease Market High Potential Countries, Segments and Strategies

    35.1 Minimal Residual Disease Market In 2029 - Countries Offering Most New Opportunities

    35.2 Minimal Residual Disease Market In 2029 - Segments Offering Most New Opportunities

    35.3 Minimal Residual Disease Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Asia-Pacific, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: China, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: China, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: China, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: India, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: India, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: India, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: Japan, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: Japan, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: Japan, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Australia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Australia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Australia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Indonesia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Indonesia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Indonesia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: South Korea, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: South Korea, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: South Korea, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: Western Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: Western Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: Western Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: UK, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: UK, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: UK, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: Germany, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: Germany, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: Germany, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: France, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: France, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: France, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: Italy, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: Italy, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: Italy, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Spain, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Spain, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Spain, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Eastern Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Eastern Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Eastern Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Russia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Russia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Russia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: North America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: North America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: North America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: USA, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: USA, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: USA, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: Canada, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: Canada, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: Canada, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: South America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: South America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: South America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: Brazil, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: Brazil, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: Brazil, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Middle East, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Middle East, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Middle East, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Africa, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Africa, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Africa, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Thermo Fisher Scientific Inc. Financial Performance
  • Table 79: Amgen Inc. Financial Performance
  • Table 80: Laboratory Corporation of America Holdings (LabCorp) Financial Performance
  • Table 81: Quest Diagnostics Incorporated Financial Performance
  • Table 82: Agilent Technologies Inc. Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Minimal Residual Disease Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Minimal Residual Disease Market, Sub-Segmentation Of Leukemia, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Minimal Residual Disease Market, Sub-Segmentation Of Solid Tumors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Minimal Residual Disease Market, Sub-Segmentation Of Other Detection Targets, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Minimal Residual Disease Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Minimal Residual Disease Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Asia-Pacific, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Asia-Pacific, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: China, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: China, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: China, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: India, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: India, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: India, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: Japan, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: Japan, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: Japan, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Australia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Australia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Australia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Indonesia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Indonesia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Indonesia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: South Korea, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: South Korea, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: South Korea, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: Western Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: Western Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: Western Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: UK, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: UK, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: UK, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: Germany, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: Germany, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: Germany, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: France, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: France, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: France, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: Italy, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: Italy, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: Italy, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Spain, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Spain, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Spain, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Eastern Europe, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Eastern Europe, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Eastern Europe, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Russia, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Russia, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Russia, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: North America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: North America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: North America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: USA, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: USA, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: USA, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: Canada, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: Canada, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: Canada, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: South America, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: South America, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: South America, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: Brazil, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: Brazil, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: Brazil, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Middle East, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Middle East, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Middle East, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Africa, Minimal Residual Disease Market, Segmentation By Detection Target, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Africa, Minimal Residual Disease Market, Segmentation By Test Technique, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Africa, Minimal Residual Disease Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Thermo Fisher Scientific Inc. Financial Performance
  • Figure 79: Amgen Inc. Financial Performance
  • Figure 80: Laboratory Corporation of America Holdings (LabCorp) Financial Performance
  • Figure 81: Quest Diagnostics Incorporated Financial Performance
  • Figure 82: Agilent Technologies Inc. Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report

Frequently Asked Questions

What is the definition of the Minimal Residual Disease market?

Minimal residual disease (MRD) refers to the few cancer cells that persist in the body after treatment, despite clinical remission. Monitoring minimal residual disease (MRD) helps detect early signs of relapse, evaluate treatment effectiveness, and predict the risk of recurrence. This sensitive detection can guide tailored therapies to improve outcomes and reduce the likelihood of relapse. For further insights on the Minimal Residual Disease market, request a sample here

How will the Minimal Residual Disease market drivers and restraints affect the market dynamics? What forces will shape the Minimal Residual Disease industry going forward?

The Minimal Residual Disease market major growth driver - Rising Cancer Prevalence Driving Growth In The Market. For further insights on the Minimal Residual Disease market, request a sample here

What is the forecast market size or the forecast market value of the Minimal Residual Disease market?

The Minimal Residual Disease market size has grown strongly in recent years. The minimal residual disease market size has grown rapidly in recent years. It will grow from $1.78 billion in 2024 to $2.01 billion in 2025 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to increasing number of cancer patients, growing research and development spending, rising healthcare affordability, rising prevalence of blood cancer, and increasing awareness among people. The minimal residual disease market size is expected to see rapid growth in the next few years. It will grow to $3.22 billion in 2029 at a compound annual growth rate (CAGR) of 12.5%. The growth in the forecast period can be attributed to rise in the number of patients with cancer, rise in the government awareness programs, rise in the healthcare affordability, increasing disposable income in emerging economies, and government body initiatives to create awareness about cancer. Major trends in the forecast period include advancements in next-generation sequencing (NGS) technology, standardization of MRD testing, adoption of personalized MRD monitoring, development in liquid biopsy technologies, minimal residual disease-directed therapies. For further insights on the Minimal Residual Disease market, request a sample here

How is the Minimal Residual Disease market segmented?

The minimal residual disease market covered in this report is segmented –
1) By Detection Target: Lymphoma, Leukemia, Solid Tumors, Other Detection Targets
2) By Test Technique: Flow Cytometry, Polymerase Chain Reaction (PCR), Next Generation Sequencing (NGS), Other Test Techniques
3) By End-User: Banking, Financial Services, And Insurance (BFSI), Retail And E-Commerce, Hospitals, Diagnostic Laboratories, Research Institutions

Subsegments:
1) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma
2) By Leukemia: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia
3) By Solid Tumors: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer
4) By Other Detection Targets: Multiple Myeloma, Neuroblastoma, Sarcomas For further insights on the Minimal Residual Disease market,
request a sample here

Which region has the largest share of the Minimal Residual Disease market? What are the other regions covered in the report?

North America was the largest region in the minimal residual disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the minimal residual disease market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Minimal Residual Disease market, request a sample here.

Who are the major players in the Minimal Residual Disease market?

Major companies operating in the minimal residual disease market are Thermo Fisher Scientific Inc., Amgen Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Sysmex Corporation, Bio-Rad Laboratories Inc., Qiagen N.V., Exact Sciences Corporation, Kite Pharma Inc., Natera Inc., Foundation Medicine Inc., NeoGenomics Inc., Guardant Health Inc., Grail LLC, Tempus AI Inc., Veracyte Inc., Adaptive Biotechnologies Corporation, Invivoscribe Inc., Mission Bio Inc., ArcherDx Inc. . For further insights on the Minimal Residual Disease market, request a sample here.

What are the key trends in the Minimal Residual Disease market?

Major trends in the Minimal Residual Disease market include Advanced In Vitro Diagnostic (IVD) Test Services For Minimal Residual Disease (MRD) Detection In Diffuse Large B-Cell Lymphoma. For further insights on the Minimal Residual Disease market, request a sample here.

What are the major opportunities in the Minimal Residual Disease market? What are the strategies for the Minimal Residual Disease market?

For detailed insights on the major opportunities and strategies in the Minimal Residual Disease market, request a sample here.

How does the Minimal Residual Disease market relate to the overall economy and other similar markets?

For detailed insights on the key dynamics influencing the Minimal Residual Disease market growth and SWOT analysis of the Minimal Residual Disease industry, request a sample here.

For detailed insights on Minimal Residual Disease's relation to the overall economy and other similar markets,

What are the latest mergers and acquisitions in the Minimal Residual Disease industry? request a sample here.

For detailed insights on the mergers and acquisitions in the Minimal Residual Disease industry,

What are the key dynamics influencing the Minimal Residual Disease market growth? SWOT analysis of the Minimal Residual Disease market. request a sample here.